Low-Dose Mesylate Salt of Paroxetine (LDMP) Had Broad Clinical Benefit Across Multiple Assessments of Vasomotor Symptoms (VMS)

被引：0
|
作者：
Portman, David [1 ]
Simon, James A. [2 ,3 ]
Blumenstein, Brent [4 ]
Shah, Snehal [5 ]
Bhaskar, Sailaja [5 ]
Lippman, Joel [5 ]
机构：
[1] Columbus Ctr Womens Hlth Res, Columbus, OH USA
[2] George Washington Univ, Sch Med, Washington, DC USA
[3] Womens Hlth & Res Consultants, Washington, DC USA
[4] Trial Architecture TriArc Consulting, Washington, DC USA
[5] Noven Pharmaceut Inc, New York, NY USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2013年 / 20卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：1350 / 1350
页数：1
相关论文
共 16 条
  • [1] Analysis of Clinical Benefit of Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms (VMS) Across Subsets Defined by Baseline Attributes
    Simon, James A.
    Portman, David
    Blumenstein, Brent
    Shah, Snehal
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1352 - 1352
  • [2] Low-Dose Mesylate Salt of Paroxetine (LDMP) Demonstrated Therapeutic Benefit for 24 Weeks in Women With Vasomotor Symptoms (VMS) Due to Menopause
    Portman, David
    Simon, James A.
    Blumenstein, Brent
    Shah, Snehal
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1349 - 1349
  • [3] Low-Dose Mesylate Salt of Paroxetine (LDMP) Reduced Daily Frequency of Moderate Vasomotor Symptoms (VMS) and Severe VMS Due to Menopause
    Kaunitz, Andrew M.
    Simon, James A.
    Kazempour, Kazem
    Mekonnen, Hana
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1340 - 1340
  • [4] Patient and Clinician Impressions of Improvement in Vasomotor Symptoms (VMS) Due to Menopause With Low-dose Mesylate Salt of Paroxetine (LDMP) Treatment
    Portman, David
    Simon, James A.
    Blumenstein, Brent
    Shah, Snehal
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1350 - 1350
  • [5] Low-Dose Mesylate Salt of Paroxetine (LDMP) Reduced Patient Burden of Menopausal Vasomotor Symptoms
    Pinkerton, JoAnn V.
    Kaunitz, Andrew M.
    Kazempour, Kazem
    Mekonnen, Hana
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1348 - 1348
  • [6] Low-Dose Mesylate Salt of Paroxetine (LDMP) Provided Therapeutic Benefit in Women With Vasomotor Symptoms (VMS) Due to Menopause and High Baseline (BL) Symptom Burden
    Simon, James A.
    Portman, David
    Blumenstein, Brent
    Shah, Snehal
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1353 - 1353
  • [7] Low-Dose Mesylate Salt of Paroxetine (LDMP) Improved Sleep in Women With Vasomotor Symptoms Due to Menopause
    Pinkerton, JoAnn V.
    Joffe, Hadine
    Kazempour, Kazem
    Mekonnen, Hana
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1347 - 1348
  • [8] Impact on Body Weight and Sexual Function During Treatment of Vasomotor Symptoms (VMS) Due to Menopause With Low-Dose Mesylate Salt of Paroxetine (LDMP)
    Kaunitz, Andrew M.
    Portman, David
    Kazempour, Kazem
    Mekonnen, Hana
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1320 - 1320
  • [9] Comparison of Two Weighted Severity Score Calculations in Phase 3 Studies Evaluating Low-Dose Mesylate Salt of Paroxetine (LDMP) for the Treatment of Vasomotor Symptoms (VMS) Due to Menopause
    Simon, James A.
    Portman, David
    Kazempour, Kazem
    Mekonnen, Hana
    Bhaskar, Sailaja
    Lippman, Joel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (12): : 1352 - 1353
  • [10] Pharmacokinetic Properties of Once-Daily Oral Low-Dose Mesylate Salt of Paroxetine (LDMP 7.5 mg) Following Single and Multiple Doses in Healthy Postmenopausal Women
    Castelli, M. Cristina
    Bhaskar, Sailaja
    Lippman, Joel
    CLINICAL THERAPEUTICS, 2013, 35 (06) : 862 - 869
12